Can PCOS be cured?

No cure for PCOS has been found. A large and profitable market sells one anyway.

One seller charges $3,600. That buys laboratory tests, a diet and supplement plan, and coaching, with more supplements sold through affiliate links on top. A woman who paid finished nearly a year later no better, and described leaving with a worse relationship to food and to their own body than before.

This is not a fringe corner of the internet. In September 2024 the BBC World Service tracked the most-watched videos carrying a PCOS hashtag on TikTok and Instagram. Half of them spread false information (Wakefield, 2024).

What is being sold, and for how much

The investigation followed the money to named sellers.

One has more than two million followers across two platforms, sells supplements at $219, and charges $29 a month for access to a weight loss app. That account warns its audience away from the birth control pill and from metformin, both of which help many people with the condition.

Many sellers describe themselves as nutritionists or hormone coaches. The BBC reports that those accreditations can be completed online in a matter of weeks.

The four claims, and the record

These came up most often across the videos the BBC counted. The investigation was published in December 2024, so the claims are quoted as they were made. The condition was renamed PMOS in May 2026, and both names are correct during the transition, which is why almost everything written about it still says PCOS.

Dr Jen Gunter, a gynaecologist quoted throughout the investigation, named the mechanism in one line.

Whenever there's a gap in medicine, predators take advantage.

Why the market exists

The gap is real, and in India it is wider than most people realise.

In 2025 a team at the Indian Council of Medical Research set out to answer a smaller question than whether the condition can be cured. Of the treatments doctors actually use for it in India, which ones work?

They gathered every proper trial run in Indian women over fourteen years, and published their method before they started, so the answer could not be picked afterwards.

They found thirty-eight. Thirty had tested drugs. Eight had tested everything else, including diet, yoga and herbal supplements.

Then they tried to put the results together, and mostly could not.

The reason is the trials themselves. They had tested different things, on different women, and measured different results. Most ran at a single hospital with few participants, and most were built in ways that leave their findings open to doubt.

Why three is a small number

One trial that helped forty women tells you about those forty women. Before anyone can say a treatment works, several trials have to point the same way, and that only counts when they asked the same question in a comparable manner. Three did.

Fourteen years of research in this country, and three.

None of this says the treatments fail. Doctors use them because they see them work, and far more has been studied outside India than inside it. It says the research done here cannot yet tell you how well any of it works.

Which leaves a strange gap. The treatments with real research behind them come with careful, hedged answers. The products with none come with total certainty, at $3,600.

What the word costs

Dr Gunter told the BBC that misinformation often causes people to delay seeking medical help, and that restrictive influencer diet plans can set off disordered eating.

The honest version is smaller than a cure and more useful. PMOS is a long-term condition. Symptoms can change a great deal with treatment, and how much they change for any one person is something the evidence cannot predict well yet.

That is a worse headline and a better basis for deciding anything. A treatment that improves a symptom is doing its job. It is fair to ask what a medicine is meant to change, by how much, how long it should take, and what happens next if it does not.

What this does not tell you

The ICMR review covers trials run in India. It does not cover the global evidence, which is larger, and it does not establish that treatments fail. It establishes that the Indian trials could not be combined to say how well they work.

The BBC investigation tracked one month of videos on two platforms, and the sellers it names are based outside India. What it documents is a market and a method rather than a measurement of how much of this reaches Indian women, which nobody has counted.

Neither source says anything about the course of the condition over years, because neither was designed to answer that.